Roth Affirms BioLineRx (BLRX( at 'Buy'; Balance Sheet Strong as BL-8040 Momentum Builds

May 17, 2016 2:15 PM

Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q1 results reported earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found